Evidence map›Paper›PMID 40688311›Full record

ArticleJournal of thoracic disease2025

Pulsed electric field ablation safety and characterization near sensitive structures in lung: a preclinical and clinical case series study.

David W Hunter, William Krimsky, R Ryan Meyerhoff, Joseph G Mammarappallil, Rosa Kaviani, William C Stoffregen, Janani Reisenauer

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

David W HunterGalvanize Therapeutics, Inc., Redwood City, CA, USA.ORCID https://orcid.org/0000-0001-9687-6645
William KrimskyGalvanize Therapeutics, Inc., Redwood City, CA, USA.
R Ryan MeyerhoffDepartment of Radiology, Duke University School of Medicine, Durham, NC, USA.
Joseph G MammarappallilDepartment of Radiology, Duke University School of Medicine, Durham, NC, USA.
Rosa KavianiGalvanize Therapeutics, Inc., Redwood City, CA, USA.
William C StoffregenNorthstar Preclinical and Pathology Services, LLC, Lake Elmo, MN, USA.
Janani ReisenauerDivision of Thoracic Surgery, Mayo Clinic, Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Since pulsed electric fields (PEFs) can ablate tissue without reliance on ionizing radiation or thermal processes, there is potential for this technique to safely ablate near sensitive structures in the lung in a way that may be distinct from thermal or radiative technologies. The purpose of this study is to demonstrate the ability of Aliya PEFs to be delivered safely in the lungs near critical structures via percutaneous and bronchoscopic access. Methods: This study evaluates performance of the Aliya PEF system in healthy swine lung tissue when specifically delivered near sensitive structures (pleura, diaphragm, large vessels and airways). Clinically, six human subjects who received PEF near similar structures are also presented. These six patients all underwent the Aliya PEF procedure because they presented with lesions adjacent to sensitive structures that were not considered candidates for traditional ablative modalities. Twelve pigs received lung ablations percutaneously (n=6) or endobronchially (n=6). Animals were followed for 3-5 days or 28 days with routine computed tomography and gross and histopathology. Results: There were no intraprocedural concerns in any of the animals, including no incidences of electrocardiogram disturbances. Gross pathology and histology confirm the onset of cell death with retained extracellular matrix integrity without clinically significant alteration of sensitive structures despite intentional device placement near (1-5 mm) these structures. There were no in-life or pathology-based safety or performance concerns and no adverse events during the treatment procedures associated with the use of Aliya System. Clinically, all the patients who received PEF tolerated the procedure well and without significant adverse sequelae. Conclusions: This PEF technology can kill cells while sparing the extracellular matrix and reducing damage to sensitive structures. This study demonstrates that the Aliya PEF may afford a safer alternative to other ablation modalities.

Indexed as

ablationcase seriescritical structuresendobronchial ablationPulsed electric fields (PEFs)

Identifiers

PMID40688311
PMCPMC12268617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.